The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

Trial Profile

The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Ocular inflammation
  • Focus Registrational; Therapeutic Use
  • Sponsors Icon Bioscience
  • Most Recent Events

    • 20 Apr 2015 According to an Icon Bioscience media release, results from this trial were presented at the 2015 Annual Symposium & Congress of the American Society of Cataract and Refractive Surgery (ASCRS) & American Society of Ophthalmic Administrators (ASOA).
    • 20 Apr 2015 Results published in the Icon Bioscience media release.
    • 06 Apr 2015 Primary endpoint has been met. (Anterior chamber cell clearing (ACC=0) in the study eye at Day 8), according to Icon Bioscience media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top